NVAX

Novavax Stock Price

93.73
2.57 (2.82%)
Upgrade to Real-Time
Afterhours (Closed)
93.73
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Level 1 Starter
Monthly Subscription
for only
$15.87
VAT not included
Company Name Stock Ticker Symbol Market Type
Novavax Inc NVAX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
2.57 2.82% 93.73 19:52:59
Close Price Low Price High Price Open Price Previous Close
93.59 88.83 95.41 90.60 91.16
Bid Price Ask Price Spread News
93.75 93.98 0.23 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
26,966 2,600,403 $ 93.27 $ 242,545,231 4,122,149 3.54 - 198.50
Last Trade Time Type Quantity Stock Price Currency
19:55:58 96 $ 93.9799 USD

Novavax Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 5.74B 61.28M 61.07M $ 18.66M $ - -5.62 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 12.96k 3.60%

more financials information »

Novavax News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NVAX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week110.27112.949988.81100.692,908,160-16.54-15.0%
1 Month98.55121.9288.81107.823,323,708-4.82-4.89%
3 Months141.00198.5083.22125.105,792,339-47.27-33.52%
6 Months23.00198.5016.4186.837,495,57170.73307.52%
1 Year4.42198.503.5455.586,430,70089.312,020.59%
3 Years21.00198.503.5437.726,753,14072.73346.33%
5 Years137.40198.503.5447.417,004,754-43.67-31.78%

Novavax Description

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.


Your Recent History
NASDAQ
NVAX
Novavax
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.